Basic Information Experimental Physicochemical Property Pharmacokinetic/Toxicokinetic Property Maximum Dosage Drug Property Radar Chart

Basic Information

Drug ID DDPD00381 ...
Drug Name Amlodipine
Molecular Weight 408.876
Molecular Formula C20H25ClN2O5
CAS Number 88150-42-9
SMILES CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
External Links
DRUGBANK DB00381
PubChem Compound 2162
PDR 1853
Drugs.com Drugs.com Drug Page

Experimental Physicochemical Property

Property Name Property Value Unit Raw Value Raw Unit Reference
Log P 3.0 - 3.0 - AUSTIN,RP ET AL. (1995)
Boiling Point 527.2 ℃ 527.2 ℃ https://www.lookchem.com/Amlodipine-besylate/
Melting Point 200.0 ℃ 199-201 ℃ https://www.chemicalbook.com/ChemicalProductProperty_US_CB4127875.aspx

Pharmacokinetic/ Toxicokinetic Property

Property Name Property Value Unit Raw Value Raw Unit Annotation Factor Reference
Absorption 100.0 % 100.0 % PO, oral; food; food → ; DRUGBANK
Bioavailability 77.0 % 64-90 % PO, oral; food; food → ; DRUGBANK
Bioavailability 74.0 % 74±17 % PO, oral; Elderly → ; The Pharmacological Basis of Therapeutics
C Max 18.1 ng/ml 18.1±7.1 ng/ml PO, oral; Male, men; adults; Elderly ↑ ; The Pharmacological Basis of Therapeutics
T Max 9.0 h 6-12 h PO, oral; food; food → ; DRUGBANK
T Max 6.7 h 5.4-8.0 h PO, oral; Male, men; adults; The Pharmacological Basis of Therapeutics
Tss 180.0 h 7-8 day PO, oral; Oral multiple dose; DRUGBANK
Metabolic 90.0 % 90 % Liver metabolism; Inactive metabolite; DRUGBANK
Metabolic 55.0 % 55 % Urinary excretion; DRUGBANK
Clearance 0.42 L/h/kg 7±1.3 ml/min/kg Total clearance; normal,healthy; Geriatric ↓ ;Age ↓ ; DRUGBANK
Clearance 0.35 L/h/kg 5.9±1.5 ml/min/kg Elderly → ;Hepatitis, Hep ↓ ;RD, renal impairment, Renal disease，including uremia → ; The Pharmacological Basis of Therapeutics
Clearance 0.42 L/h/kg 7 ml/min/kg intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Volume of Distribution 21.0 L/kg 21.0 L/kg DRUGBANK
Volume of Distribution 16.0 L/kg 16±4 L/kg Elderly → ; The Pharmacological Basis of Therapeutics
Volume of Distribution 17.0 L/kg 17 L/kg intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Half-life 40.0 h 30-50 h elimination half-life; DRUGBANK
Half-life 39.0 h 39±8 h RD, renal impairment, Renal disease，including uremia → ;Hepatitis, Hep ↑ ;Age ↑ ; The Pharmacological Basis of Therapeutics
Half-life 34.0 h 34 h intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Toxicity LD50 37.0 mg/kg 37.0 mg/kg PO, oral; mouse; DRUGBANK
Eliminate Route 10.0 % 10 % Urinary excretion; Unchanged drug; DRUGBANK
Eliminate Route 10.0 % 10 % Urinary excretion; Unchanged drug; The Pharmacological Basis of Therapeutics
Protein Binding 98.0 % ~98 % DRUGBANK
Protein Binding 93.0 % 93±1 % Elderly → ; The Pharmacological Basis of Therapeutics

Maximum Dosage

Property Name Property Value Unit Raw Value Raw Unit Annotation Brand Name Component Reference
Max dose for children 5.0 mg/day 5 mg/day PO, oral Norvasc amlodipine besylate PDR
Max dose for children 0.6 mg/kg/day 0.6 mg/kg/day PO, oral Norvasc amlodipine besylate PDR
Max dose for children 20.0 mg/day 20 mg/day PO, oral Norvasc amlodipine besylate PDR
Max dose for children 0.6 mg/kg/day 0.6 mg/kg/day PO, oral Norvasc amlodipine besylate PDR
Max dose for children 20.0 mg/day 20 mg/day PO, oral Norvasc amlodipine besylate PDR
Max dose for adolescents 5.0 mg/day 5 mg/day PO, oral Norvasc amlodipine besylate PDR
Max dose for adolescents 0.6 mg/kg/day 0.6 mg/kg/day PO, oral Norvasc amlodipine besylate PDR
Max dose for adolescents 20.0 mg/day 20 mg/day PO, oral Norvasc amlodipine besylate PDR
Max dose for adults 10.0 mg/day 10 mg/day PO, oral Norvasc amlodipine besylate PDR
Max dose for geriatric 10.0 mg/day 10 mg/day PO, oral Norvasc amlodipine besylate PDR

Drug Property Radar Chart

...

Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1